Our company is at the forefront of small molecule drug development, providing comprehensive services to pharmaceutical companies worldwide. Through our expertise in target identification, lead compound screening, and preclinical safety assessment, we aim to accelerate the discovery and development of small molecule drugs including proteolysis targeting chimera, molecular glue degraders, and SMDC.

Through our expertise in cell biology, molecular biology, and translational research, we assist in the identification and characterization of suitable cell types for specific therapeutic applications. We also offer guidance in optimizing cell culture conditions, developing appropriate cell expansion protocols, and establishing quality control measures to ensure the consistent and reproducible production of therapeutic cells.

Gene therapy development represents a groundbreaking approach to rare diseases, aiming to address diseases at their genetic roots. Before progressing to clinical trials, thorough preclinical studies and safety assessments are crucial to evaluate the effectiveness and safety profiles of gene therapy candidates. We guide in optimizing gene delivery systems and ensuring the safety and efficacy of the gene therapy product.

As this field continues to flourish, our company stands at the forefront, armed with an expansive repertoire of antibody discovery technologies. From the classical hybridoma technology to the versatile phage display technology and the cutting-edge single B cell antibody screening technology, we harness the power of innovation to unlock the potential of therapeutic antibodies.

Peptides have emerged as a pivotal tool in the treatment of diverse ailments. We have accumulated valuable experience in modified peptides, cyclic peptides, nano-peptides, and long peptide research, coupled with our state-of-the-art platform and technical strength, our team is ready to provide customized solutions for your rare disease projects.

Therapeutic proteins, with their ability to replace abnormal or deficient proteins, hold immense promise in the treatment of specific diseases. At our company, we are proud to offer therapeutic protein development platforms, including fusion protein development and recombinant protein development, that not only deliver superior results but also prioritize cost-effectiveness.

By employing advanced bioinformatics analysis, our company can uncover valuable insights into the genetic basis of diseases, facilitating the development of targeted therapies and personalized treatment plans. Meanwhile, our company specializes in biomarker discovery and validation, utilizing advanced techniques such as genomics, proteomics, and metabolomics.

Our company stands at the forefront of the burgeoning field of rare disease therapeutics technology. We have carefully established a sound and mature therapy development process system, from target discovery to preclinical research, designed to meet your specific needs.

Drug repurposing, a practice also referred to as drug repositioning or drug reprofiling, entails repurposing existing compounds for novel therapeutic applications in different diseases. We excel in screening and evaluating these compounds, identifying their potential for new therapeutic purposes, particularly in the realm of rare diseases.

Rare disease models encompass experimental systems designed to emulate the pathophysiology and clinical manifestations of rare diseases within a controlled laboratory environment. Our expertise spans the generation, validation, and characterization of rare disease models, including the development of genetically engineered models, transplant models, humanized models, and other models.

Drawing upon our extensive expertise in rare disease therapy research, and bolstered by a legacy of excellence, innovation, and unwavering customer support, our company offers comprehensive drug safety evaluation services to both established biopharmaceutical companies and emerging scientific research institutions, including general toxicology, genetic toxicology, developmental and reproductive toxicity.

Pharmacokinetics (PK) encompasses the study of drug absorption, distribution, metabolism, and excretion, collectively referred to as "ADME." We offer a comprehensive range of pharmacokinetic services, spanning from early drug discovery to preclinical research, with a singular focus on expediting your research endeavors in the realm of rare disease treatment.